487-06-9

Basic information

• Product Name: 5,7-Dimethoxycoumarin
• Synonyms: 2H-1-Benzopyran-2-one, 5,7-dimethoxy-;5,7-dimethoxy-2h-1-benzopyran-2-on;5,7-Dimethoxy-2H-chromen-2-one;5,7-dimethoxy-coumari;5,7-dimethyloxy-2H-1-benzopyran-2-one;Citraptene;Coumarin, 5,7-dimethoxy-;5,7-DIMETHOXY-CHROMEN-2-ONE
• CAS NO: 487-06-9
• Molecular Formula: C₁₁H₁₀O₄
• Molecular Weight: 206.19
• EINECS: 207-646-4
• Product Categories: Coumarins;API intermediates;Inhibitors
• Mol File: 487-06-9.mol
• Article Data: 24

Chemical Properties

• Melting Point: 146-149 °C(lit.)
• Boiling Point: 305.04°C (rough estimate)
• Flash Point: 176.3 °C
• Appearance: YELLOW TO TAN OR BROWN POWDER OR CRYSTALLINE POWDER
• Density: 1.2607 (rough estimate)
• Vapor Pressure: 3.13E-06mmHg at 25°C
• Refractive Index: 1.4570 (estimate)
• Storage Temp.: 2-8°C
• Solubility: Acetonitrile (Slightly), Chloroform (Slightly)
• Merck: 14,5492
• CAS DataBase Reference: 5,7-Dimethoxycoumarin(CAS DataBase Reference)
• NIST Chemistry Reference: 5,7-Dimethoxycoumarin(487-06-9)
• EPA Substance Registry System: 5,7-Dimethoxycoumarin(487-06-9)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• WGK Germany: 3
• RTECS: GN6530000
• Hazardous Substances Data: 487-06-9(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 487-06-9 differently. You can refer to the following data:
1. photosensitizing agent
2. 5,7-Dimethoxycoumarin is a derivitized coumarin compound.

Synthesis Reference(s)

Journal of the American Chemical Society, 118, p. 6305, 1996 DOI: 10.1021/ja961107i

General Description

5,7-dimethoxycoumarin is isolated and identified from leaves and fruits of Pelea anisata H. Mann, a plant whose fruit are used in the construction of mohikana leis. It induces frameshift mutagenesis in bacteria. It also causes lethal photosensitization and the formation of sister chromatid exchanges in Chinese hamster cells.

Biochem/physiol Actions

5,7-Dimethoxycoumarin induces the processes of differentiation and melanogenesis in murine (B16) and human (A375).

InChI:InChI=1/C11H10O4/c1-13-7-5-9(14-2)8-3-4-11(12)15-10(8)6-7/h3-6H,1-2H3

Upstream product

• 500-99-2 3,5-dimethoxyphenol 
• 623-47-2 propynoic acid ethyl ester 
• 121449-70-5 3-bromo-3,5-dimethoxyphenol 
• 471-25-0 Propiolic acid 
• 15568-85-1 5-methoxymethylene-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 23133-74-6 1-acetoxy-3,5-dimethoxy-benzene 
• 292638-85-8 acrylic acid methyl ester 
• 708-76-9 2-hydroxy-4,6-dimethoxybenzaldehyde 
• 616-38-6 carbonic acid dimethyl ester 
• 21204-67-1 methyl (triphenylphosphoranylidene)acetate 
• 105-58-8 Diethyl carbonate 
• 140-88-5 ethyl acrylate 
• 82235-61-8 ethyl 5,7-dimethoxy-2-oxo-2H-chromene-3-carboxylate 
• 85-32-5 Guanosine 5'-monophosphate 

Downstream Products

• 108-73-6 3,5-dihydroxyphenol 
• 64-19-7 acetic acid 
• 1151668-19-7 4-(4-chlorophenyl)-5,7-dimethoxychroman-2-one 
• 1415387-93-7 3-(4-chlorophenyl)-1-(cis-3,5-dimethylpiperidin-1-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)propan-1-one 
• 1415387-95-9 1-(cis-3,5-dimethylpiperidin-1-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)-3-(3-methoxyphenyl)propan-1-one 
• 1415387-92-6 1-(cis-3,5-dimethylpiperidin-1-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-(trifluoromethyl)phenyl)propan-1-one 
• 1427192-78-6 C₁₈H₁₆O₆ 
• 1427192-07-1 4-(3-(3,5-cis-dimethlpiperidin-1-yl)-3-oxo-1-(2,4,6-trimethoxyphenyl)-propyl)benzoic acid 
• 1427192-08-2 4-(3-(3,5-cis-dimethylpiperidin-1-yl)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-oxopropyl)benzoic acid 
• 1427192-12-8 1-(3,5-dimethylpiperidin-1-yl)-3-(4,6-dimethoxy-2-hydroxy-phenyl)-3-(2-methoxypyrid-5-yl)propan-1-one 
• 1427192-76-4 4-(3-(3,5-cis-dimethylpiperidin-1-yl)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-oxopropyl)benzoic acid, sodium salt 
• 17245-25-9 coumurrayin 
• 1334470-43-7 3-(3-(3,5-dimethylpiperidin-1-yl)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-oxopropyl)benzonitrile 

Relevant articles and documents

Amido compounds as RORγt modulators and uses thereof

Amido compounds are disclosed that have a formula represented by the following: and wherein Cy1, Cy2, n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.

Rh-Catalyzed Synthesis of Coumarin Derivatives from Phenolic Acetates and Acrylates via C-H Bond Activation

An efficient annulation strategy involving the reaction of phenolic acetates with acrylates in the presence of [Rh2(OAc)4] as catalyst and formic acid as reducing agent, leading to the high yield synthesis of coumarin derivatives, has been developed. The addition of NaOAc as a base increased the yield of the products. The reaction is quite successful for both electron-rich as well as electron-deficient phenolic acetates, affording coumarins with excellent regioselectivity, and proceeds via C-H bond activation proven by deuterium incorporation studies.

AMIDO COMPOUNDS AS RORGAMMATMODULATORS AND USES THEREOF

Amido compounds are disclosed that have a formula represented by the following: 1 and wherein Cy1, Cy2, n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graftversus-host disease